Nonarteritik Anterior İskemik Optik Nöropati Tedavisinde Güncel Yaklaşımlar

Yıl 2022, Cilt: 7 Sayı: 3, 98 - 102, 01.12.2022

Hatice Kübra Sönmez

Öz

Nonarteritik anterior iskemik optik nöropati (NAİON), 50 yaş üzeri erişkinlerde ani ve ağrısız görme kaybı sebebidir. Hastalığın etyopatogenezinde pek çok teori ortaya atılmakla birlikte en yaygın kabul edilen posterior silier dolaşımdaki bozulmalara bağlı akut iskemi gelişmesidir. Hastalıkta bazı tedavi yöntemleri uygulansa da etkileri sınırlıdır ve halen kesin bir tedavi yöntemi bulunmamaktadır. Bu derleme, NAİON hastalığında geliştirilen güncel yöntemleri değerlendirerek uygulanabilecek tedavi stratejilerine katkı sağlamayı amaçlamaktadır.

Anahtar Kelimeler

Nonarteritik anterior iskemik optik nöropati, NAİON, optik nöropati

Destekleyen Kurum

Yok

Proje Numarası

Yok

Teşekkür

Yok

Kaynakça

• 1. Reis AS, Sharpe GP, Yang H, Nicolela MT, Burgoyne CF, Chauhan BC. Optic disc margin anatomy in patients with glaucoma and normal controls with spectral domain optical coherence tomography. Ophthalmology. 2012 Apr;119(4):738-47. doi: 10.1016/j.ophtha.2011.09.054.
• 2. Lee MS, Grossman D, Arnold AC, Sloan FA. Incidence of nonarteritic anterior ischemic optic neuropathy: increased risk among diabetic patients. Ophthalmology. 2011; 118: 959-63. doi: 10.1016/j.ophtha.2011.01.054.
• 3. Hayreh SS, Joos KM, Podhajsky PA, Long CR.Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1994;118: 766-80. doi: 10.1016/s0002-9394(14)72557-7.
• 4. Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nonarteritic anterior ischemic optic neuropathy: role of nocturnal arterial hypotension. Arch Ophthalmol. 1997; 115: 942-5. doi: 10.1001/archopht.1997.01100160112031.
• 5. Wu Y, Zhou LM, Lou H, Cheng JW, Wei RL.The Association Between Obstructive Sleep Apnea and Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis. CurrEyeRes. 2016; 41:987-92. doi: 10.3109/02713683.2015.1075221.
• 6. Jonas JB. Optic disc morphology and NAAION. Br J Ophthalmol. 2009;93:703. doi: 10.1136/bjo.2008.155630.
• 7. Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-basedstudy in the state of Missouriand Los AngelesCounty, California. J Neuroophthalmol. 1994;14:38–44.
• 8. Hayreh SS. Ischemic optic neuropathy. Prog Retin Eye Res. 2009;28: 34-62. doi: 10.1016/j.preteyeres.2008.11.002.
• 9. Biousse V, Newman NJ. Ischemic Optic Neuropathies. N Engl J Med. 2015 Jun 18;372(25):2428-36. doi: 10.1056/NEJMra1413352. Erratum in: N Engl J Med. 2015 Dec 10;373(24):2390.
• 10. Stunkel L, Van Stavern GP. Steroid Treatment of Optic Neuropathies. Asia Pac J Ophthalmol (Phila). 2018 Jul-Aug;7(4):218-228. doi: 10.22608/APO.2018127.
• 11. Hayreh SS, Zimmerman MB. Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):1029-46. doi: 10.1007/s00417-008-0805-8.
• 12. Takayama K, Kaneko H, Kachi S, Ra E, Ito Y, Terasaki H. High-dose intravenous pulse steroid therapy for optic disc swelling and subretinal fluid in non-arteritic anterior ischemic optic neuropathy. Nagoya J Med Sci. 2017 Feb;79(1):103-108. doi: 10.18999/nagjms.79.1.103.
• 13. Rebolleda G, Pérez-López M, Casas-LLera P, Contreras I, Muñoz-Negrete FJ. Visual and anatomical outcomes of non-arteritic anterior ischemic optic neuropathy with high-dose systemic corticosteroids. Graefes Arch Clin Exp Ophthalmol. 2013 Jan;251(1):255-60. doi: 10.1007/s00417-012-1995-7.
• 14. Chen J, Zhu J, Chen L, Hu C, Du Y. Steroids in the treatment of nonarteritic anterior ischemic optic neuropathy: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2019 Nov;98(46):e17861. doi: 10.1097/MD.0000000000017861.
• 15. Saxena R, Singh D, Sharma M, James M, Sharma P, Menon V. Steroids versus No Steroids in Nonarteritic Anterior Ischemic Optic Neuropathy: A Randomized Controlled Trial. Ophthalmology. 2018 Oct;125(10):1623-1627. doi: 10.1016/j.ophtha.2018.03.032.
• 16. Durbant E, Radoi C, Garcia T, Denoyer A, Arndt C. Intravitreal triamcinolone injections in non-arteritic anterior ischemic optic neuropathy - A retrospective report. J Fr Ophtalmol. 2021 Jun;44(6):777-785. doi: 10.1016/j.jfo.2020.07.027. 17. Salomon O, Huna-Baron R, Steinberg DM, Kurtz S, Seligsohn U. Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. Eye (Lond). 1999 Jun;13 ( Pt 3a):357-9. doi: 10.1038/eye.1999.90.
• 18. Beck RW, Hayreh SS, Podhajsky PA, Tan ES, Moke PS. Aspirin therapy in nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997 Feb;123(2):212-7. doi: 10.1016/s0002-9394(14)71038-4.
• 19. Kwon SU, Kim JS. Antithrombotic Therapy. Front Neurol Neurosci. 2016;40:141-151. doi: 10.1159/000448310.
• 20. Lai YF, Lin TY, Ho PK, Chen YH, Huang YC, Lu DW. Erythropoietin in Optic Neuropathies: Current Future Strategies for Optic Nerve Protection and Repair. Int J Mol Sci. 2022 Jun 27;23(13):7143. doi: 10.3390/ijms23137143.
• 21. García-Ramírez, M.; Hernández, C.; Simó, R. Expression of erythropoietin and its receptor in the human retina: A comparative study of diabetic and nondiabetic subjects. Diabetes Care 2008, 31, 1189–1194. doi: 10.2337/dc07-2075.
• 22. Dreixler, J.C.; Hagevik, S.; Hemmert, J.W.; Shaikh, A.R.; Rosenbaum, D.M.; Roth, S. Involvement of erythropoietin in retinal ischemic preconditioning. Anesthesiology 2009, 110, 774–780. doi: 10.1097/ALN.0b013e31819c4601.
• 23. Nikkhah H, Golalipour M, Doozandeh A, Pakravan M, Yaseri M, Esfandiari H. The effect of systemic erythropoietin and oral prednisolone on recent-onset non-arteritic anterior ischemic optic neuropathy: a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2020 Oct;258(10):2291-2297. doi: 10.1007/s00417-020-04781-x.
• 24. Pakravan M, Esfandiari H, Hassanpour K, Razavi S, Pakravan P. The Effect of Combined Systemic Erythropoietin and Steroid on Non-arteritic Anterior Ischemic Optic Neuropathy: A Prospective Study. Curr Eye Res. 2017 Jul;42(7):1079-1084. doi: 10.1080/02713683.2016.1270328.
• 25. Abri Aghdam K, Aghajani A, Ashraf Khorasani M, Soltan Sanjari M, Chaibakhsh S, Habibi A, Falavarjani KG. Intravitreal Injection Of The Granulocyte-Colony Stimulating Factor For The Treatment Of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Pilot Study. Semin Ophthalmol. 2021 Nov 17;36(8):649-657. doi: 10.1080/08820538.2021. 26. Liu PK, Wen YT, Lin W, Kapupara K, Tai M, Tsai RK. Neuroprotective effects of low-dose G-CSF plus meloxicam in a rat model of anterior ischemic optic neuropathy. Sci Rep. 2020 Jun 25;10(1):10351. doi: 10.1038/s41598-020-66977-9.
• 27. Chiquet C, Vignal C, Gohier P, Heron E, Thuret G, Rougier MB, Lehmann A, Flet L, Quesada JL, Roustit M, Milea D, Pepin JL; ENDOTHELION group. Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol. Trials. 2022 Oct 29;23(1):916. doi: 10.1186/s13063-022-06786-9.
• 28. Chien JY, Chou YY, Ciou JW, Liu FY, Huang SP. The Effects of Two Nrf2 Activators, Bardoxolone Methyl and Omaveloxolone, on Retinal Ganglion Cell Survival during Ischemic Optic Neuropathy. Antioxidants (Basel). 2021 Sep 15;10(9):1466. doi: 10.3390/antiox10091466.
• 29. Chou YY, Chien JY, Ciou JW, Huang SP. The Protective Effects of n-Butylidenephthalide on Retinal Ganglion Cells during Ischemic Injury. Int J Mol Sci. 2022 Feb 14;23(4):2095. doi: 10.3390/ijms23042095.
• 30. Rootman DB, Gill HS, Margolin EA. Intravitreal bevacizumab for the treatment of nonarteritic anterior ischemic optic neuropathy: a prospective trial. Eye (Lond). 2013 Apr;27(4):538-44. doi: 10.1038/eye.2012.296.
• 31. Prescott CR, Sklar CA, Lesser RL, Adelman RA. Is intravitreal bevacizumab an effective treatment option for nonarteritic anterior ischemic optic neuropathy? J Neuroophthalmol. 2012 Mar;32(1):51-3. doi: 10.1097/WNO.0b013e318240596e.
• 32. Dave VP, Pappuru RR. An unusual presentation of nonarteritic ischemic optic neuropathy with subretinal fluid treated with intravitreal bevacizumab. Indian J Ophthalmol. 2016 Jan;64(1):87-8. doi: 10.4103/0301-4738.178143.
• 33. Fugara NA, Shawareb ZA, Rakkad NK, Barhoum ML, Shawareb BA, Al-Madani MM, Al-Madani MV. The Risk of Non-arteritic Ischemic Optic Neuropathy Post-intravitreal Bevacizumab Injection. Cureus. 2022 Oct 11;14(10):e30185. doi: 10.7759/cureus.30185.